This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Aripiprazole as the Causative Agent of Neuroleptic Malignant Syndrome

Daniel Molina, MD, LT; Leslie E. Tingle, MD; and Xiaohui Lu, MD

Published: April 16, 2007

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Neuroleptic malignant syndrome (NMS) is a rare and potentially life-threatening neurologic emergency commonly associated with the use of antipsychotic medications. As a class, atypical antipsychotic agents have lower associated rates of extrapyramidal symptoms and are less likely to induce NMS as compared to conventional antipsychotics. One of the newest agents in the atypical antipsychotic class is aripiprazole

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 9

Quick Links: Neuroleptic Malignant Syndrome , Side Effects-Medication


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...